Remune

Remune is an immunotherapy treatment developed by Immune Response Corporation for HIV/AIDS. It is an inactivated form of the HIV-1 virus, designed to stimulate an immune response against the virus in patients already infected with HIV.

History

Remune was developed by the Immune Response Corporation, a biopharmaceutical company based in Carlsbad, California. The company was founded in 1986 by Dr. Robert C. Gallo, a co-discoverer of the HIV virus, and Dr. Ronald Moss, a specialist in infectious diseases. The development of Remune began in the late 1980s, with the aim of creating a therapeutic vaccine for HIV/AIDS.

Mechanism of Action

Remune works by stimulating the body's immune system to fight against HIV. It is made from an inactivated form of the HIV-1 virus, which has been genetically engineered to remove the gp120 protein. This protein is responsible for the virus's ability to infect cells, so its removal renders the virus non-infectious. When injected into the body, Remune triggers an immune response against the virus, helping to control its spread and reduce the severity of symptoms.

Clinical Trials

Several clinical trials have been conducted to test the safety and efficacy of Remune. These trials have shown that the treatment is generally well-tolerated, with few side effects. However, the results regarding its efficacy have been mixed. Some studies have found that Remune can help to control viral load and delay the progression of HIV/AIDS, while others have found no significant benefit.

Current Status

As of 2021, Remune is not currently approved for use by the Food and Drug Administration (FDA) in the United States. However, it is still being studied in clinical trials, and further research may lead to its approval in the future.

See Also

• HIV/AIDS
• Immunotherapy
• HIV-1
• gp120
• Food and Drug Administration